通过将其灵活的域间连接器与序列选择性结合纳米颗粒结合,对抗多药性蛋白1进行控制
Avijit Ghosh1, Mansi Sharma1, Yan Zhao1
1Department of Chemistry, Iowa State University, Ames, Iowa 50011-3111, United States.
Biomacromolecules
|February 17, 2026
概括
分子打印的纳米粒子准多药耐药性蛋白1 (MRP1) 来克服癌症药物耐药性. 这种新的方法抑制了排泄,使耐化学疗的癌细胞敏感,并降低了药物IC50值.
科学领域:
- 生物化学 生物化学
- 纳米技术纳米技术
- 癌症研究 癌症研究
背景情况:
- 过度表达的ATP结合盒 (ABC) 载体,如多药耐药蛋白1 (MRP1),通过驱逐药物驱动癌症中的多药耐药性.
- 类似的排泄过度表达有助于细菌的抗微生物耐药性.
研究的目的:
- 开发序列选择性,分子印记纳米粒子 (MINPs),以向和抑制人类癌细胞中的MRP1.
- 研究MINPs在癌症治疗中克服药物耐药性的潜力.
主要方法:
- 设计用于绑定MRP1灵活链接器的特定段的MINP的制造.
- 细胞测试以评估MINP结合对MRP1功能和药物敏感性的影响.
- 用MINP和多克索鲁比辛治疗的耐多克斯癌细胞的IC50值的确定.
主要成果:
- MINP成功地掩盖了MRP1链接器的部分,抑制了排水的功能.
- 在内膜接口附近绑定MINP显著降低了MRP1活动.
- 用MINP治疗的抗多克斯癌细胞对多克索鲁比的敏感性增加,IC50.5降低了约25%.
结论:
- MINPs代表了一种抑制细胞内蛋白质的新策略,特别针对MRP1.
- 这种方法可以通过使细胞对化疗敏感来克服癌症中的多药耐药性.
- 简单的蛋白质基因 (MINP) 便于在非结构蛋白区域中识别功能线性基因.
相关概念视频
Protein Digestion
Protein digestion begins in the stomach, where the highly acidic environment can easily disrupt protein structure by exposing the peptide bonds of polypeptide chains. After polypeptide chains are broken into individual amino acids by a series of digestive enzymes, the amino acids are transported to the liver via the bloodstream to produce energy.
Protein Absorption
Proteins in the gastrointestinal tract typically come from food, but they can also originate from disintegrated cells or secreted enzymes. In the stomach, the enzyme pepsin breaks down these proteins into polypeptides. The fragments then move into the duodenum as a semi-fluid mass called chyme. Pancreatic proteases, such as trypsin and chymotrypsin, and intestinal brush border enzymes like carboxypeptidases further dismantle the polypeptides into tripeptides, dipeptides, and free amino acids.
Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


